Literature DB >> 10362811

Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women.

C Szych1, A Staebler, D C Connolly, R Wu, K R Cho, B M Ronnett.   

Abstract

Pseudomyxoma peritonei (PMP) is a poorly understood condition characterized by mucinous ascites and multifocal peritoneal mucinous tumors. Women with PMP often have mucinous tumors involving both the appendix and the ovaries. Several previous histopathological and immunohistochemical studies of PMP have suggested that most, if not all, cases of PMP in women are derived from mucinous adenomas of the appendix rather than from primary ovarian tumors. A few studies of the molecular genetics of PMP have been recently reported. However, these studies analyzed only a small number of cases and some included a heterogeneous group of mucinous tumors, including both benign and malignant appendiceal and ovarian tumors. We analyzed K-ras mutations and allelic losses of chromosomes 18q, 17p, 5q, and 6q in a substantial number of morphologically uniform cases of PMP with synchronous ovarian and appendiceal tumors as well as in appendiceal mucinous adenomas (MAs) and ovarian mucinous tumors of low malignant potential (MLMPs) unassociated with PMP. Each of the 16 PMP cases (100%) analyzed demonstrated identical K-ras mutations in the appendiceal adenoma and corresponding synchronous ovarian tumor. K-ras mutations were identified in 11 of 16 (69%) appendiceal MAs unassociated with PMP and in 12 of 16 (75%) ovarian MLMPs unassociated with PMP. Two PMP cases showed identical allelic losses in the matched ovarian and appendiceal tumors. A discordant pattern of allelic loss between the ovarian and appendiceal tumors at one or two of the loci tested was observed in six PMP cases. In all but one instance, LOH was observed in the ovarian tumor, whereas both alleles were retained in the matched appendiceal lesion, suggesting tumor progression in a secondary (metastatic) site. Our findings strongly support the conclusion that mucinous tumors involving the appendix and ovaries in women with PMP are clonal and derived from a single site, most likely the appendix.

Entities:  

Mesh:

Year:  1999        PMID: 10362811      PMCID: PMC1866622          DOI: 10.1016/S0002-9440(10)65442-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  16 in total

1.  Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations.

Authors:  M Cuatrecasas; X Matias-Guiu; J Prat
Journal:  Am J Surg Pathol       Date:  1996-06       Impact factor: 6.394

2.  Early involvement of 6q in surface epithelial ovarian tumors.

Authors:  M G Tibiletti; B Bernasconi; D Furlan; C Riva; M Trubia; G Buraggi; M Franchi; P Bolis; A Mariani; L Frigerio; C Capella; R Taramelli
Journal:  Cancer Res       Date:  1996-10-01       Impact factor: 12.701

3.  Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression.

Authors:  C Guerrieri; B Frånlund; S Fristedt; J F Gillooley; B Boeryd
Journal:  Hum Pathol       Date:  1997-09       Impact factor: 3.466

4.  Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women.

Authors:  B M Ronnett; B M Shmookler; M Diener-West; P H Sugarbaker; R J Kurman
Journal:  Int J Gynecol Pathol       Date:  1997-01       Impact factor: 2.762

5.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

6.  Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer.

Authors:  I E Cooke; A N Shelling; V G Le Meuth; M L Charnock; T S Ganesan
Journal:  Genes Chromosomes Cancer       Date:  1996-04       Impact factor: 5.006

7.  K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.

Authors:  M Cuatrecasas; A Villanueva; X Matias-Guiu; J Prat
Journal:  Cancer       Date:  1997-04-15       Impact factor: 6.860

8.  Cytogenetic analysis of several pseudomyxoma peritonei lesions originating from a mucinous cystadenoma of the appendix.

Authors:  M R Teixeira; H Qvist; K E Giercksky; P J Bøhler; S Heim
Journal:  Cancer Genet Cytogenet       Date:  1997-02

9.  Rapid identification of patient specimens with microsatellite DNA markers.

Authors:  T D Kessis; M A Silberman; M Sherman; L Hedrick; K R Cho
Journal:  Mod Pathol       Date:  1996-03       Impact factor: 7.842

10.  Genetic analysis of synchronous mucinous tumors of the ovary and appendix.

Authors:  R F Chuaqui; Z Zhuang; M R Emmert-Buck; B R Bryant; F Nogales; F A Tavassoli; M J Merino
Journal:  Hum Pathol       Date:  1996-02       Impact factor: 3.466

View more
  41 in total

1.  In support of findings on Pseudomyxoma peritonei.

Authors:  S J Urbanski
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

3.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

4.  Controversial origin of Pseudomyxoma peritonei.

Authors:  Alejandro Rojo Sebastián; Francisco José Fernández Morejón; Pedro Bretcha Boix; José Farré Alegre; Jerónimo Forteza Vila; Antonio Brugarolas Masllorens
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

5.  Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.

Authors:  Kevin M Elias; S Intidhar Labidi-Galy; Allison F Vitonis; Jason L Hornick; Leona A Doyle; Michelle S Hirsch; Daniel W Cramer; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2013-12-14       Impact factor: 5.482

6.  Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.

Authors:  Jerome T O'Connell; James S Tomlinson; Alice A Roberts; Kathryn F McGonigle; Sanford H Barsky
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Two independent primary mucinous tumors involving the appendix and ovary accompanied with acellular pseudomyxoma peritonei.

Authors:  Feng Zhou; Xiaoduan Chen; Yinghua Li; Lili Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.

Authors:  Tommaso Cioppa; Marco Vaira; Camilla Bing; Silvia D'Amico; Alessandro Bruscino; Michele De Simone
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

9.  Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4).

Authors:  Chin-Fan Chen; Che-Jen Huang; Wan-Yi Kang; Jan-Sing Hsieh
Journal:  World J Surg Oncol       Date:  2008-11-11       Impact factor: 2.754

10.  Bevacizumab for the Treatment of Non-Resectable Pseudomyxoma peritonei Associated with Mucinous Ovarian Tumor of Low Malignant Potential - A Comparison of Two Cases.

Authors:  Ira Winer; Ronald J Buckanovich
Journal:  Case Rep Oncol       Date:  2009-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.